Marvin Baula, MD
Psychiatry · Middletown, OHNPI 1104156819
Payments from drug & device makers
Across 1,075 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Axsome Therapeutics, Inc.$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $7K from 17 others
What the payments were for
- Speaking & faculty fees$5003%
- Food & beverage$16,82696%
- Education$1511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 75 | $2,258 |
| Axsome Therapeutics, Inc. | 77 | $2,003 |
| Alkermes, Inc. | 131 | $1,696 |
| Teva Pharmaceuticals USA, Inc. | 117 | $1,632 |
| AbbVie | 120 | $1,481 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 117 | $1,371 |
| Vanda Pharmaceuticals Inc. | 66 | $1,349 |
| Lundbeck LLC | 93 | $1,056 |
| Otsuka America Pharmaceutical, Inc. | 74 | $975 |
| E.r. Squibb & Sons, L.L.C. | 51 | $965 |
| Supernus Pharmaceuticals, Inc. | 15 | $874 |
| Neurocrine Biosciences, Inc. | 33 | $407 |
| Sunovion Pharmaceuticals Inc. | 31 | $359 |
| Almatica Pharma LLC | 13 | $301 |
| Corium, LLC | 17 | $189 |
| Tris Pharma Inc | 18 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $168 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $92 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Sage Therapeutics, LLC | 1 | $22 |
| Braeburn Inc. | 1 | $18 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$498
- LYBALVI$488
- Auvelity$476
- INVEGA SUSTENNA$475
- INVEGA TRINZA$230
- COBENFY$221
- ARISTADA INITIO$125
How this compares
$17,477 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $147,365 |
| RexultiBrexpiprazole | 73 | $106,229 |
| VraylarCariprazine Hcl | 62 | $94,090 |
| Invega SustennaPaliperidone Palmitate | 21 | $74,338 |
| TrintellixVortioxetine Hydrobromide | 57 | $30,276 |
| Lurasidone Hcl | 84 | $22,058 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,753 |
| Aripiprazole | 288 | $12,168 |
| Paliperidone ErPaliperidone | 29 | $6,376 |
| Divalproex Sodium ErDivalproex Sodium | 46 | $4,528 |
| Quetiapine Fumarate | 256 | $4,040 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 79 | $3,769 |
| Oxcarbazepine | 90 | $3,287 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 23 | $3,287 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 119 | $3,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,632 | $147,36513 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $975 | $106,22973 claims |
| AbbVieVraylar | $1,481 | $94,09062 claims |
| Johnson & JohnsonInvega Sustenna | $2,258 | $74,33821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $168 | $44,02993 claims |
| Almatica Pharma LLCSertraline Hcl | $301 | $1,010205 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Middletown
- Emad AlshamiMiddletown$98K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.